The MDS Hub
is an open-access online resource dedicated to providing balanced, reliable, and up-to-date medical education in myelodysplastic syndromes (MDS) and will be launched today.
With the opening of our new hub, our aim is to enhance knowledge of MDS through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management. To achieve this, the MDS Hub will share novel evidence-based articles, drug and trial updates, expert opinions, and disseminate international congress coverage to clinicians and scientists around the world.
MDS is the term given to a diverse group of disorders of the bone marrow in which progenitor blood cells do not mature properly and, therefore, do not form fully functional cells. The advent of novel agents for the treatment of MDS is promising but there are still many areas requiring improvement such as risk assessment, treatment-associated toxicities, and the management of cytopenia-associated complications.
Our vision is to give clinical teams and academic researchers alike the opportunity to access cutting-edge information on MDS and expert opinions, which will inform and guide therapeutic strategies and improve the lives of the patients under their care. The mission of the MDS Hub is to increase the shared knowledge base on MDS through multimedia channels, and lift the collective awareness of this group of cancers while giving healthcare professionals evidence-based articles to aid disease management and treatment decision making.
The MDS Hub has been founded in partnership with the European LeukemiaNet (ELN) in 2020 and is guided by an international Steering Committee of experts in the field of MDS. The Steering Committee meets regularly to discuss the performance of the MDS Hub and devise action plans on how to best support the MDS community and address any unmet educational needs.
"The MDS Hub allows you to get access to the most relevant and up-to-date information in myelodysplastic syndromes and related disorders. We aim to deliver valuable and up-to-date information from recently published papers and expert interviews to all physicians practicing hemato-oncology", Professor Theo de Witte, Chair of the MDS Hub, is based at the Radboud University Medical Center, Nijmegen, Netherlands.
Professor Theo de Witte joins the Steering Committee of the MDS Hub together with some of the worldwide experts in MDS and hematology-oncology research, including Uwe Platzbecker, Moshe Mittelman, Valeria Santini, Pierre Fenaux, David Bowen, Alexandra Smith, Rena Buckstein, Eva Hellström-Lindberg, Rafael Bejar, Mikkael Sekeres, Silvia Magalhães, Guillermo Garcia-Manero, and Yasushi Miyazaki.
The MDS Hub owes thanks to the support of its founding industry partners, Novartis
(Silver) and BMS
(Bronze), without whom the platform would not be possible.
Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which include the Lymphoma Hub, AML Hub, Multiple Myeloma Hub, GvHD Hub, and MPN Hub.
For more information on the MDS Hub, please visit mds-hub.com.
For media enquiries or to explore collaboration opportunities, please contact email@example.com
Press release distributed by Pressat on behalf of Scientific Education Support, on Friday 4 December, 2020. For more information subscribe and follow https://pressat.co.uk/